Remove Books Remove Dosage Remove FDA
article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA 65
article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

But together, they contribute to the ever-expanding expectation that oncology pharmacists should “know all the things,” an emotion aptly captured by Allie Brosh in her book Hyperbole and a Half. Touchstone Books; 2013. Time Enough for Love. Putnam’s Sons; 1973. Rao KV, Gulbis AM, Mahmoudjafari Z.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investigating the Pharmacist’s Role in Psychedelic-Assisted Psychotherapy for Patients With Cancer

Pharmacy Times

In the 2017 book The Big Picture , author Sean Carroll seamlessly blends the scientific with the philosophical and comments that “life is not a substance, like water or rock; it’s a process, like fire or a wave crashing on the shore. Potential Roles of the Oncology Pharmacist My friend died of his metastatic cancer in early 2025.

article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

The FDA Law Blog

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

Dosage 116
article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

The FDA Law Blog

Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. Last week, the FTC held a Listening Session about the listing of patents in the Orange Book, which concluded with a unanimous vote to issue a Policy Statement.

FDA 106
article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

The FDA Law Blog

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book.

FDA 59
article thumbnail

The Streams Have Been Crossed: FTC Enters FDA Territory

The FDA Law Blog

” At least that’s this blogger’s reaction to the recent news that FTC sent out Notice letters to 10 different drug companies about the patent information they list in the Orange Book. As FTC explains in a Press Release , the Agency “challenged more than 100 patents” that it believes are improperly or inaccurately listed in the Orange Book.

FDA 59